Cost-effectiveness analysis of gestational diabetes mellitus screening in France.
OBJECTIVE
To compare three strategies for gestational diabetes screening (i) screening of high-risk pregnant women with the 50 g oral glucose tolerance test (OGTT); (ii) screening of all pregnant women with the 50 g OGTT; (iii) screening of all pregnant women according to the 75 g OGTT.


METHODS
Cost-effectiveness analysis. The outcome measures, i.e. macrosomia, prematurity, perinatal mortality, hypertensive disorders rates were estimated from published studies and the costs from a prospective study involving 120 pregnant women.


RESULTS
Compared to the first strategy, the cost to obtain one unit of additional effectiveness with the second screening strategy, was up to 1.1 times more expensive, and with the third strategy was up to 3.7 times more expensive.


CONCLUSIONS
The costs per case prevented reflect a favourable cost-effectiveness ratio (CER) for screening of high-risk pregnant women by 50 g oral glucose test.
Poncet
Bénédicte
B
Unité d'évaluation médico-économique, Département d'Information Médicale, Hospices Civils de Lyon, LASS-UMR 5823 CNRS, 162 Avenue Lacassagne, 69424 Cedex 03, Lyon, France. benedicte.poncet@chu-lyon.fr
Touzet
Sandrine
S
Rocher
Laure
L
Berland
Michel
M
Orgiazzi
Jacques
J
Colin
Cyrille
C
D003362:Cost-Benefit Analysis; D016640:Diabetes, Gestational / Q000175:diagnosis* / Q000453:epidemiology; D005260:Female; D005320:Fetal Macrosomia / Q000453:epidemiology / Q000517:prevention & control; D005602:France / Q000453:epidemiology; D005951:Glucose Tolerance Test / Q000191:economics; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D008403:Mass Screening / Q000191:economics*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control; D011446:Prospective Studies; D012307:Risk Factors